Results from the EXSCEL trial suggest that peripheral artery disease (PAD) patients were less likely to be on optimal medical therapy for secondary prevention of cardiovascular (CV) disease, specifically statins, beta-blockers, ACE inhibitors, and aspirin . Although large studies in patients with diabetes have identified agents that lower major adverse cardiovascular event (MACE) rates, certain agents increase rates of lower extremity amputation (LEA). Especially patients with peripheral artery disease run a risk, as they have a greater incidence of diabetes and risk for lower extremity amputation.
The EXSCEL study tested the effects of the GLP-1 agonist exenatide vs placebo on the rates of the primary composite MACE endpoint (i.e. CV death, myocardial infarction, or stroke) and a post-hoc analysis assessed the association of PAD with rates of MACE, LEA, and the effects of exenatide vs placebo in patients with and without PAD. The 2,800 enrolled PAD pat...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Lower rates stroke/SE with DOACs in frail non-valvular AF patients Next Article
Venetoclax-obinutuzumab combination elicits high response rates in CLL »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.